Loading…
Amphastar Pharmaceuticals, Inc. is projected to rise to $20.43 by 2027, a +7% move from its current price of $19.10. AMPH is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $18.61 | $19.11 | $19.62 | +0.03% |
| May 30 | $18.41 | $19.11 | $19.84 | +0.06% |
| May 31 | $18.26 | $19.12 | $20.01 | +0.08% |
| Jun 1 | $18.14 | $19.12 | $20.16 | +0.11% |
| Jun 2 | $18.03 | $19.13 | $20.29 | +0.14% |
| Jun 3 | $17.94 | $19.13 | $20.41 | +0.17% |
| Jun 4 | $17.85 | $19.14 | $20.52 | +0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $17.85 | $19.14 | $20.52 | +0.20% |
| Week 2 | $17.37 | $19.18 | $21.16 | +0.39% |
| Week 3 | $17.03 | $19.21 | $21.68 | +0.59% |
| Week 4 | $16.74 | $19.25 | $22.13 | +0.79% |
| Week 5 | $16.50 | $19.29 | $22.54 | +0.99% |
| Week 6 | $16.29 | $19.33 | $22.93 | +1.19% |
| Week 7 | $16.10 | $19.36 | $23.29 | +1.39% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Amphastar Pharmaceuticals, Inc. is a healthcare company in the bio-pharmaceutical space that develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. Its product portfolio includes BAQSIMI, Primatene MIST, Glucagon for injection emergency kit, Enoxaparin, REXTOVY, and Naloxone for opioid overdose, among others.
It also provides Cortrosyn, Amphadase, Epinephrine injection for allergic reactions, Lidocaine jelly and Lidocaine topical solution, Phytonadione injection for newborns, and emergency syringe products. In addition, Amphastar offers Albuterol sulfate inhalation aerosol, Iron sucrose injection, Teriparatide injection, Ipratropium Bromide HFA inhalation aerosol, and active pharmaceutical ingredients such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Amphastar Pharmaceuticals, Inc. trades in the Healthcare sector under the AMPH ticker. The stock is currently priced at $18.41, with a market capitalization of $811.75M and a market rank of 2683.
The price outlook shows upside potential over the multi-year horizon, with the forecast projecting higher average prices and meaningful returns later in the cycle. By 2030 the average price is forecast at $25.95 and by 2050 the average price is forecast at $95.63, with long-run ROIs reaching as high as 419.5%.
A major floor 32.8% below — a decisive break under it would weaken the trend.
The nearest floor, 11.7% below — buyers have tended to step in here.
The nearest ceiling, 25.8% above — a clean break opens room to run.
A major ceiling 53.2% above — clearing it would confirm fresh momentum.
Key AMPH support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AMPH market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $18.51 | Buy | $18.60 | Buy |
| MA 10 | $18.01 | Buy | $18.63 | Buy |
| MA 20 | $19.73 | Sell | $19.25 | Sell |
| MA 50 | $20.22 | Sell | $20.51 | Sell |
| MA 100 | $22.90 | Sell | $22.04 | Sell |
| MA 200 | $24.88 | Sell | $24.18 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.67 | Neutral |
| Stoch RSI (14) | 40.81 | Neutral |
| CCI (20) | -19.51 | Neutral |
| Williams %R (14) | -68.85 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 0.53 | Buy |
| Bollinger %B (20,2) | 0.43 | Neutral |
| Stochastic %K (14) | 31.15 | Neutral |
| TRIX (15) | -0.54 | Sell |
| Awesome (5,34) | -1.96 | Sell |
| Ultimate (7,14,28) | 71.33 | Sell |
| Momentum (10) | 1.60 | Buy |
| Aroon Osc (25) | -24.00 | Sell |
| Hull MA (9) | 19.01 | Buy |
| ADX (14) | 21.73 | Sell |
| ATR (14) | 0.57 | Info |
The near-term technical picture is BEARISH, with an RSI14 reading of 40. The stock’s 50-day simple moving average sits at $20.22 and the 200-day simple moving average is at $24.92. Near-term support is at $16.87 and resistance at $24.03, suggesting a down-to-neutral tilt in the immediate horizon.
The 30-day price range runs from $15.36 to $22.06, and the stock exhibits relatively high volatility, around 50%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.87 | $19.10 | $24.15 | 0% | Neutral | |
| $16.26 | $20.43 | $27.17 | +7% | Neutral | |
| $16.99 | $21.91 | $30.17 | +15% | Neutral | |
| $19.04 | $25.11 | $35.52 | +31% | Bullish | |
| $21.79 | $29.29 | $42.42 | +53% | Bullish | |
| $23.99 | $32.82 | $48.51 | +72% | Bullish | |
| $26.33 | $36.62 | $55.12 | +92% | Bullish | |
| $25.69 | $36.29 | $55.54 | +90% | Bullish | |
| $25.94 | $37.19 | $57.79 | +95% | Bullish | |
| $27.87 | $40.52 | $63.87 | +112% | Bullish | |
| $40.88 | $63.34 | $105.99 | +232% | Bullish | |
| $69.66 | $120.42 | $219.94 | +530% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $16.87 | $19.10 | $22.38 | +0.00% |
| June 2026 | $16.17 | $18.98 | $22.79 | -0.63% |
| July 2026 | $16.56 | $19.60 | $23.84 | +3.25% |
| August 2026 | $16.74 | $19.93 | $24.48 | +1.68% |
| September 2026 | $16.23 | $19.42 | $24.06 | -2.53% |
| October 2026 | $15.97 | $19.20 | $23.96 | -1.13% |
| November 2026 | $16.11 | $19.46 | $24.44 | +1.35% |
| December 2026 | $15.76 | $19.11 | $24.15 | -1.80% |
Click any year to see its month-by-month AMPH forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, AMPH is projected to trade between $16.87 and $24.15, averaging $19.10 — a potential gain of 0% from today's $19.10. A consolidation phase looks the most probable path here.
Amphastar Pharmaceuticals, Inc.'s 2027 outlook centres on $20.43, within a $16.26 to $27.17 range. That is up +7% on the projected 2026 average. That marks a +7% change versus current levels. Price action looks broadly range-bound.
By 2028, AMPH could reach as high as $30.17, with a base case around $21.91 and support toward $16.99 — roughly +15% from $19.10. A consolidation phase looks the most probable path here.
Expect AMPH to range from $19.04 to $35.52 through 2029. The $25.11 average target implies a +31% move from current prices. That is up +15% on the projected 2028 average. Momentum favours further upside here.
The AMPH price prediction for 2030 points to an average of $29.29 (low $21.79, high $42.42) — a potential gain of +53% on today's $19.10. Buyers look set to stay in control over this stretch.
In 2031, AMPH is projected to trade between $23.99 and $48.51, averaging $32.82 — a potential gain of +72% from today's $19.10. That is up +12% on the projected 2030 average. Momentum favours further upside here.
Amphastar Pharmaceuticals, Inc.'s 2032 outlook centres on $36.62, within a $26.33 to $55.12 range. That is up +12% on the projected 2031 average. That marks a +92% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, AMPH could reach as high as $55.54, with a base case around $36.29 and support toward $25.69 — roughly +90% from $19.10. Momentum favours further upside here.
Expect AMPH to range from $25.94 to $57.79 through 2034. The $37.19 average target implies a +95% move from current prices. That is up +2% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The AMPH price prediction for 2035 points to an average of $40.52 (low $27.87, high $63.87) — a potential gain of +112% on today's $19.10. Momentum favours further upside here.
In 2040, AMPH is projected to trade between $40.88 and $105.99, averaging $63.34 — a potential gain of +232% from today's $19.10. That is up +56% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Amphastar Pharmaceuticals, Inc.'s 2050 outlook centres on $120.42, within a $69.66 to $219.94 range. That is up +90% on the projected 2040 average. That marks a +530% change versus current levels. Momentum favours further upside here.
Investing $1,000 in AMPH today (≈ 52.356021 AMPH) could be worth
$6,304.84
+$5,304.84 (+530%) by 2050 · US Dollar
Based on the average projected AMPH price of $120.42 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AMPHwould be worth at today's price.
$1,000 invested in AMPH on May 27, 2025 (≈ 39.169603 AMPH) would be worth
$748.14
-$251.86 (-25.2%) today · 0.75× · US Dollar
Based on a AMPH entry price of $25.53 vs. today's $19.1.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $18.08 | $1,056.42 | +5.6% |
| 1 month ago | $21.65 | $882.22 | -11.8% |
| 3 months ago | $26.49 | $721.03 | -27.9% |
| 6 months ago | $27.7 | $689.53 | -31.0% |
| 1 year ago | $25.53 | $748.14 | -25.2% |
| All time (5.0y) ago | $19.08 | $1,001.05 | +0.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AMPH forecast.
Our base-case forecast reaches $38.00 around 2035.
Implied market cap at $38.00: $1.68B
The multi-year forecast shows a clear bullish trajectory after the mid-term, with the average price climbing from 2026 through 2032 and beyond. In 2026, the avg is $18.41 with an ROI of 0%; by 2027 the avg rises to $19.13 (ROI 3.9%), and in 2028 to $20.16 (ROI 9.5%). The path continues higher, with 2029 average $22.29 (ROI 21.1%), 2030 $25.95 (ROI 40.9%), 2031 $29.12 (ROI 58.1%), and 2032 $32.00 (ROI 73.8%).
The forecast stays bullish through 2033 ($31.53 avg, ROI 71.3%), 2034 ($31.93 avg, ROI 73.4%), and 2035 ($34.21 avg, ROI 85.8%). Longer-horizon estimates show substantial upside, with 2040 average $52.81 (ROI 186.9%) and 2050 average $95.63 (ROI 419.5%). These figures indicate meaningful long-run appreciation but remain subject to market conditions and inherent uncertainty in any forecast.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $25.95 with a range from $19.17 to $37.89 and an estimated ROI of 40.9%. The sentiment for 2030 is BULLISH.
The outlook shows rising average prices and a path to higher ROIs later in the forecast, with ROI reaching 40.9% by 2030, 58.1% by 2031, and up to 419.5% by 2050. However, 2026 projects a 0% ROI and near-term sentiment is Neutral to Bearish, so outcomes are uncertain and not guaranteed.
Yes. The forecast shows a max of $54.51 in 2035, and higher maxima of $89.49 in 2040 and $177.26 in 2050, indicating potential to exceed $50 in the coming years.
The near-term outlook is bearish with a 14-day RSI of 40. The stock trades around a 50-day SMA of $20.22 and a 200-day SMA of $24.92, with near-term support at $16.87 and resistance at $24.03. The 30-day range is $15.36 to $22.06, and volatility is high at about 50%.
The current price is $18.41 and the market capitalization is $811.75M. The stock rank is 2683.
Amphastar Pharmaceuticals, Inc. Community Discussion
0Share your Amphastar Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.